NASDAQ: MTRYMonterey Bio Acquisition Corp Stock
$10.56+0.06 (+0.57%)
Updated Jan 27, 2023
MTRY Price
$10.56
Fair Value Price
N/A
Market Cap
$51.68M
52 Week Low
$9.90
52 Week High
$10.65
P/E
-62.12x
P/B
-72.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-165.75
Operating Cash Flow
-$2M
Beta
0
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MTRY Overview
Monterey Bio Acquisition Corporation is a special purpose acquisition company (SPAC) formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the biotech industry. Monterey Bio Acquisition was incorporated in 2020 and is headquartered in New York, NY.
Zen Score
–
Industry Average (7)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MTRY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MTRY is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
MTRY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more MTRY due diligence checks available for Premium users.
Be the first to know about important MTRY news, forecast changes, insider trades & much more!
MTRY News
Valuation
MTRY fair value
Fair Value of MTRY stock based on Discounted Cash Flow (DCF)
Price
$10.56
Fair Value
$10.41
Overvalued by
1.46%
MTRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MTRY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-62.12x
Industry
15.79x
Market
23.59x
MTRY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-72.49x
Industry
-34.04x
MTRY's financial health
Profit margin
Revenue
$0.0
Net Income
-$420.5k
Profit Margin
0%
MTRY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$117.5M
Liabilities
$118.2M
Debt to equity
-165.75
MTRY's short-term liabilities ($97.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTRY's long-term liabilities ($20.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTRY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MTRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$121.3k
Investing
$0.0
Financing
$361.4k
MTRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MTRY vs Shell Company Stocks
Monterey Bio Acquisition Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.